Innovative BioTherapies, Inc. (IBT) specializes in the development of bioartificial organ-based devices, leveraging advanced technologies that include adult progenitor cells, biomaterials, and microelectromechanical systems (MEMs). Founded in 2003 by Dr. H. David Humes, the company aims to commercialize innovative solutions derived from research conducted in his academic laboratory. The focus on bioartificial organs highlights IBT's commitment to addressing critical medical needs through the integration of biological and engineering principles.

The company's research and development efforts are primarily funded through federal grants and contracts, underscoring the significance of their work in the field of regenerative medicine. By utilizing adult progenitor cells, IBT aims to create devices that can mimic the functions of natural organs, potentially transforming treatment options for patients with organ failure. The incorporation of biomaterials and MEMs technology further enhances the functionality and effectiveness of these bioartificial devices, positioning IBT at the forefront of biotechnological innovation.

United States

Innovative BioTherapies (IBT) is a small biotechnology company located in Ann Arbor, MI, focused on developing medical devices to solve unmet medical needs.

Innovative BioTherapies

Company Details